Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tablet tech could transform breast cancer diagnosis in nigeria

NCT ID NCT05561842

Diagnosis Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study trains Nigerian radiologists to use tablet-based ultrasound to guide breast biopsies, a method that is more accurate than the blind biopsies or surgical excisions currently used. Nine hundred women with suspicious breast lumps will participate. The goal is to make this advanced diagnostic technique sustainable and widely available in Nigeria.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could make breast cancer diagnosis more accurate and accessible in Nigeria, reducing the need for blind biopsies or surgery.
What could go wrong
This is a training study, not a treatment trial. Success depends on radiologists learning the technique and it being adopted in practice. Results may not apply to other settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 900 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2022

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will be accrued in medical clinics as determined by the local investigators and local research staff. Informed consent forms approved by each local IRB will be obtained by research staff from each site.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 and older female. * Breast ultrasound demonstrating a solid mass that is suspicious for cancer, which would typically undergo either a blind biopsy or surgical excision at the Nigerian hospital where the patient is seeking diagnosis. Exclusion Criteria: * Participants unwilling to sign consent. * Participants under the age of 18.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm female breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Breast cancer female

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Federal Medical Centre Owo (Data Collection Only)

    RECRUITING

    Owo, Ondo State, Nigeria

  • Lagos University Teaching Hospital

    RECRUITING

    Idi-Araba, Lagos, Nigeria

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)

    RECRUITING

    New York, New York, 10065, United States

  • Obafemi Awolowo University Teaching Hospitals Complex (Data Collection Only)

    RECRUITING

    Ile-Ife, Nigeria

  • Olabisis Onabanjo University Teaching Hospital (Data Collection Only)

    ACTIVE_NOT_RECRUITING

    Sagamu, Ogun State, Nigeria

  • University College Hospital (Data Collection Only)

    ACTIVE_NOT_RECRUITING

    Ibadan, Oyo State, Nigeria

  • University Of Nigeria Teaching Hospital (UNTH) Ituku-Ozalla Enugu

    RECRUITING

    Enugu, Nigeria

  • University of Ilorin Teaching Hospitals

    ACTIVE_NOT_RECRUITING

    Ilorin, Nigeria

More trials for these conditions

Other studies related to the condition(s) this trial covers.